» Articles » PMID: 34647586

Predictive Ability of Longitudinal Changes in PRECISE-DAPT Score in Patients on Dual Antiplatelet Therapy: The RE-SCORE Multicentre Prospective Registry

Citing Articles

Feasibility of anticoagulation on demand after percutaneous coronary intervention in high-bleeding risk patients with paroxysmal atrial fibrillation: the INTERMITTENT registry.

Pelliccia F, Zimarino M, Giordano M, Dobrev D Eur Heart J Digit Health. 2024; 5(5):637-642.

PMID: 39318681 PMC: 11417476. DOI: 10.1093/ehjdh/ztae046.


Supporting appropriate use of extended dual antiplatelet therapy post-myocardial infarction based on an innovative 12-month ticagrelor virtual service.

Khatib R, Barrowcliff A, Wilson F, Awan S, Khan M, Wheatcroft S Front Cardiovasc Med. 2024; 11:1399899.

PMID: 39314765 PMC: 11417623. DOI: 10.3389/fcvm.2024.1399899.


Should We Use Aspirin or P2Y Inhibitor Monotherapy in Stable Ischemic Heart Disease?.

Chandiramani R, Mehta A, Blumenthal R, Williams M Curr Atheroscler Rep. 2024; 26(11):649-658.

PMID: 39243345 DOI: 10.1007/s11883-024-01234-2.


Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention.

Pelliccia F, Gragnano F, Pasceri V, Cesaro A, Zimarino M, Calabro P J Clin Med. 2022; 11(13).

PMID: 35806860 PMC: 9267626. DOI: 10.3390/jcm11133574.


Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.

Jourdi G, Godier A, Lordkipanidze M, Marquis-Gravel G, Gaussem P Front Cardiovasc Med. 2022; 9:805525.

PMID: 35155631 PMC: 8832164. DOI: 10.3389/fcvm.2022.805525.